Skip to main content
Erschienen in: Inflammation 4/2019

07.03.2019 | ORIGINAL ARTICLE

TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response

verfasst von: Feng Zheng, Nannan Xu, Yajun Zhang

Erschienen in: Inflammation | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Type I interferon (IFN) response is central for host defense against viral infection. Tripartite motif 27 (TRIM27) is implicated in antiviral innate immune response; however, whether it affects the replication of hepatitis C virus (HCV) and the underlying mechanisms remain uncharacterized. Here, we show that TRIM27 expression is induced in Huh7.5 human hepatoma cells infected with HCV or stimulated with type I IFNs in vitro. In addition, TRIM27 overexpression increases and its knockdown decreases viral RNA and protein levels, suggesting that TRIM27 positively regulates HCV replication. Mechanistically, TRIM27 inhibits type I IFN response against HCV infection through inhibiting IRF3 and NF-κB pathways, since TRIM27 mutant unable to inhibit these two inflammatory pathways fails to promote HCV replication. Taken together, this study identifies TRIM27 as a novel positive regulator of HCV replication, and also implicates that targeting TRIM27 may serve as a therapeutic strategy for controlling HCV replication.
Literatur
11.
Zurück zum Zitat Saadoun, D., M. Resche Rigon, V. Thibault, M. Longuet, S. Pol, F. Blanc, G. Pialoux, A. Karras, D. Bazin-Karra, C. Cazorla, D. Vittecoq, L. Musset, O. Decaux, J.M. Ziza, O. Lambotte, and P. Cacoub. 2014. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases 73 (5): 831–837. https://doi.org/10.1136/annrheumdis-2012-202770.CrossRefPubMed Saadoun, D., M. Resche Rigon, V. Thibault, M. Longuet, S. Pol, F. Blanc, G. Pialoux, A. Karras, D. Bazin-Karra, C. Cazorla, D. Vittecoq, L. Musset, O. Decaux, J.M. Ziza, O. Lambotte, and P. Cacoub. 2014. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases 73 (5): 831–837. https://​doi.​org/​10.​1136/​annrheumdis-2012-202770.CrossRefPubMed
16.
19.
Zurück zum Zitat Zhou, Z., X. Jia, Q. Xue, Z. Dou, Y. Ma, Z. Zhao, Z. Jiang, B. He, Q. Jin, and J. Wang. 2014. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proceedings of the National Academy of Sciences of the United States of America 111 (2): E245–E254. https://doi.org/10.1073/pnas.1316941111.CrossRefPubMed Zhou, Z., X. Jia, Q. Xue, Z. Dou, Y. Ma, Z. Zhao, Z. Jiang, B. He, Q. Jin, and J. Wang. 2014. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proceedings of the National Academy of Sciences of the United States of America 111 (2): E245–E254. https://​doi.​org/​10.​1073/​pnas.​1316941111.CrossRefPubMed
31.
Zurück zum Zitat Taylor, R.T., K.J. Lubick, S.J. Robertson, J.P. Broughton, M.E. Bloom, W.A. Bresnahan, and S.M. Best. 2011. TRIM79alpha, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host & Microbe 10 (3): 185–196. https://doi.org/10.1016/j.chom.2011.08.004.CrossRef Taylor, R.T., K.J. Lubick, S.J. Robertson, J.P. Broughton, M.E. Bloom, W.A. Bresnahan, and S.M. Best. 2011. TRIM79alpha, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host & Microbe 10 (3): 185–196. https://​doi.​org/​10.​1016/​j.​chom.​2011.​08.​004.CrossRef
Metadaten
Titel
TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response
verfasst von
Feng Zheng
Nannan Xu
Yajun Zhang
Publikationsdatum
07.03.2019
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2019
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-019-00992-5

Weitere Artikel der Ausgabe 4/2019

Inflammation 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.